New attack on tough prostate cancer: Anti-Inflammatory drug joins the fight
NCT ID NCT05960578
Summary
This study is testing whether adding an anti-inflammatory drug (golimumab) to a standard prostate cancer hormone blocker (apalutamide) can better control a very advanced form of the disease. It's for men whose cancer has spread and stopped responding to standard hormone treatments. The goal is to see if this combination can slow the cancer's growth more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.